NCT03009344View on ClinicalTrials.gov

A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

January 10, 2017

Primary Completion Date

July 12, 2017

Study Completion Date

June 17, 2020

Conditions
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Interventions
DRUG

Tazemetostat

Tazemetostat tablets.

Trial Locations (2)

Unknown

Eisai Trial Site, Isehara

Eisai Trial Site, Chuo-ku

All Listed Sponsors
lead

Eisai Co., Ltd.

INDUSTRY

NCT03009344 - A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter